Leveraging Affinity Interactions to Prolong Drug Delivery of Protein Therapeutics

• Published in: Pharmaceutics Vol. 14; no. 5; p. 1088
• Main Authors: Dogan, Alan B, Dabkowski, Katherine E, von Recum, Horst A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.05.2022; MDPI
• Subjects: affinity; antibody; Autoimmune diseases; cyclodextrin; Drug delivery systems; Drugs; Hydrogels; Monoclonal antibodies; NMR; Nuclear magnetic resonance; Payloads; Peptides; Polymers; protein therapeutics; Proteins; sustained drug delivery; United States > US; sustained drug delivery; antibody; protein therapeutics; cyclodextrin; affinity
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14051088

While peptide and protein therapeutics have made tremendous advances in clinical treatments over the past few decades, they have been largely hindered by their ability to be effectively delivered to patients. While bolus parenteral injections have become standard clinical practice, they are insufficient to treat diseases that require sustained, local release of therapeutics. Cyclodextrin-based polymers (pCD) have been utilized as a platform to extend the local delivery of small-molecule hydrophobic drugs by leveraging hydrophobic-driven thermodynamic interactions between pCD and payload to extend its release, which has seen success both in vitro and in vivo. Herein, we proposed the novel synthesis of protein-polymer conjugates that are capped with a "high affinity" adamantane. Using bovine serum albumin as a model protein, and anti-interleukin 10 monoclonal antibodies as a functional example, we outline the synthesis of novel protein-polymer conjugates that, when coupled with cyclodextrin delivery platforms, can maintain a sustained release of up to 65 days without largely sacrificing protein structure/function which has significant clinical applications in local antibody-based treatments for immune diseases, cancers, and diabetes.